Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) President and CEO Mihael Hristos Polymeropoulos has recently increased his stake in the company. According to a recent SEC filing, Polymeropoulos purchased a total of 10,000 shares of Vanda Pharmaceuticals common stock on March 6, 2025. The shares were acquired at prices ranging from $5.01 to $5.02, amounting to a total expenditure of $50,150. The purchase price aligns closely with the current market price of $4.91, with analysts setting price targets ranging from $5 to $20. InvestingPro analysis indicates the stock is currently undervalued.

Following these transactions, Polymeropoulos now owns a total of 2,295,731 shares directly. This move reflects the executive’s continued confidence in the company’s prospects. Vanda Pharmaceuticals, based in Washington, D.C., is known for its focus on pharmaceutical preparations. The company maintains strong financial health with a current ratio of 4.39 and impressive gross profit margins of 94.31%. InvestingPro subscribers can access 8 additional key insights about VNDA’s financial performance and growth prospects, including detailed insider trading analysis and comprehensive valuation metrics.

In other recent news, Vanda Pharmaceuticals reported its fourth-quarter 2024 earnings, revealing a revenue of $53.2 million, which exceeded the forecast of $51.23 million. The company’s earnings per share (EPS) also surpassed expectations, coming in at -$0.08 compared to the anticipated -$0.17. This positive performance was highlighted by a 17% year-over-year increase in revenue. Despite these results, Vanda posted a net loss of $18.9 million for the year, a shift from a net income of $2.5 million in 2023, largely due to increased competition and strategic investments.

Additionally, H.C. Wainwright raised its price target for Vanda Pharmaceuticals to $20.00, maintaining a Buy rating, following the company’s financial results. The firm adjusted its revenue forecast for 2025 to $225 million, down from $235 million, while Vanda’s guidance for 2025 is set between $210 million and $250 million. Cantor Fitzgerald also reiterated its Overweight rating with a $13.00 price target, emphasizing Vanda’s potential growth trajectory by the end of 2025.

In other developments, Vanda Pharmaceuticals announced the development of an antisense oligonucleotide (ASO) therapeutic, VCA-894A, for Charcot-Marie-Tooth disease Type 2S, which has received orphan designation from the FDA. The company also disclosed changes in executive compensation, including bonuses and restricted stock units, aligning with industry standards. These recent developments reflect Vanda’s strategic focus on expanding its product line and addressing high unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.